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Cancer is the leading cause of childhood death by disease.  
 
Acute Lymphoblastic Leukaemia (ALL) is the most common paediatric malignancy. In high-risk 
paediatric ALL, chemotherapy alone may not provide a cure, in these patients haematopoietic stem 
cell transplantation is offered with curative intent. 
 
This study aims to use transplant related outcomes and pharmacogenomics to lay the foundations 
for personalised dosing for thiotepa in paediatric haematopoietic stem cell transplantation to reduce 
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Background: Haematopoietic stem cell transplant (HCT) is offered with curative intent to high-risk 
patients with acute lymphoblastic leukaemia (ALL). The polyfunctional alkylating agent thiotepa is a 
preparative regimen agent that provides profound myelosuppression and facilitates engraftment. 
There is a wide range of variability in CYP2B6, CYP3A4 and glutathione-S-transferase (GST) mediated 
thiotepa metabolism as well an inducible process in the presence of other drugs. This leads to 
variability in alkylation and potential effectiveness as a preparative regimen agent.  
 
Aim: Identify genetic variants in key metabolising enzymes that impact drug efficacy and toxicity of 
thiotepa as conditioning chemotherapy in paediatric ALL transplant patients.  
 
Methods: A retrospective pharmacogenomic experiment using stored marrow samples evaluated 
the association between HCT outcomes and single nucleotide polymorphisms (SNPs) of drug 
metabolising enzymes. Time to event analyses determined the association between SNPs and 
transplant outcomes. Multivariate analysis was performed taking significant p values from univariate 
analysis and applying a regression model using stepwise elimination. 
 
Results: 55 patients received a thiotepa based regimen for first HCT for ALL between 2000-2017 and 
had an available tumour bank sample. Eight unique SNPs for nine outcomes were identified to have 
an association with survival, engraftment and toxicity.  
 
Overall Survival was 78.18% at median 50 months follow up and was reduced in rs2740574 (T;T) 
76.9%, compared to 100% in CYP3A4*1B carrier rs2740574 (C;T) (p=0.001). rs776746 encoding non-
functional CYP3A5*3 had a detrimental effect on leukaemia free survival (LFS) with 67.7% LFS in 
 xxvii 
rs776746 (C;C) CYP3A5*3/*3 compared to 87.5% LFS for (C;T) CYP3A5*1/*3 and 100% LFS for 
rs776746 (T;T) CYP3A5*1/*1 compared to 70.9% overall (p = 0.021). LFS was also reduced in 
rs1046428 a missense variant SNP associated with glutathione-S-Transferase Z1 (p=0.049).  
 
The median time to neutrophil engraftment was 19 days. GSTT2 rs140188 (C;G) was associated with 
accelerated engraftment (p = 0.026). The median time to platelet engraftment was 29 days. 
rs8192709 (C;T) CYP2B6*1/CYP2B6*2 demonstrated delayed platelet engraftment, median 47 days 
(p = 0.000385). Mismatch, donor gender and rs8192709 (C;T) were independent risk factors for 
delayed platelet engraftment (p = 0.00003).  
 
Due to extensive and rapid distribution into the CNS, a hallmark toxicity of thiotepa is CNS adverse 
events. rs3211371 encoding CYP2B6*5 resulted in reduced CNS toxicity compared to CYP2B6*1 
(p=0.01). There was a concerning trend to increased CNS relapse in the *5 allele however this wasn’t 
significant (p = 0.0546).  
 
Conclusion: This study identified thiotepa as a potential target for pharmacogenomic guided dosing 
in the paediatric HCT setting. Thiotepa efficacy and toxicity are modified by key polymorphisms in 
drug metabolising enzymes. The identification of SNPs in drug metabolising enzymes offers an 
opportunity to tailor drug therapy based on the pharmacogenome of the transplant recipient and 
lays the foundation for personalised therapeutic dosing strategies in high risk leukaemia.  
